Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with Fulvestrant in ER+ Metastatic Breast Cancer
NCT01142401Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2010
- Primary completion
- Jul 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in breast cancer (3 arms), sponsored by National Cancer Institute. Primary endpoints: Number of Participants With Progression Free Survival (PFS) at 12 Months and Number of Participants With Progression Free Survival (PFS) at 6 Months. Started May 2010; status: completed.
02
Drugs
bortezomib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01142401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01142401.